Eli Lilly and Company (LLY)vsSotera Health Co (SHC)
LLY
Eli Lilly and Company
$1,102.08
+0.92%
HEALTHCARE · Cap: $1.01T
SHC
Sotera Health Co
$15.74
+0.32%
HEALTHCARE · Cap: $4.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 5976% more annual revenue ($72.25B vs $1.19B). LLY leads profitability with a 35.0% profit margin vs 9.9%. LLY appears more attractively valued with a PEG of 1.52. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SHC
Strong Buy68
out of 100
Grade: B-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Strong operational efficiency at 31.3%
Earnings expanding 175.4% YoY
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SHC
The strongest argument for SHC centers on Operating Margin, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : SHC
The primary concerns for SHC are PEG Ratio, P/E Ratio, Free Cash Flow. Debt-to-equity of 3.65 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while SHC is a value play — different risk/reward profiles.
SHC carries more volatility with a beta of 1.80 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 68/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sotera Health Co
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?